How are exposure patterns linked to biological pathways? Environmental chemical exposures can significantly influence drug metabolism, therapeutic response, and disease biology—but they are often overlooked in biomedical research and clinical development. In this episode of ChatGJP, Ethan Stancliffe, Senior Director of R&D, explains how environmental chemicals interact with cytochrome P450 enzymes, why chemical exposure burden […]
ChatGJP: Discovery vs Targeted Exposomics Explained Should you use discovery exposomics or targeted exposomics? In this episode of ChatGJP, Panome Bio CEO Ed Weinstein explains the strengths of each approach and how they work together to provide a comprehensive understanding of environmental chemical exposures. Discovery exposomics is an untargeted, hypothesis-generating strategy that screens broadly for […]
ChatGJP: Exposomics, PFAS, and Clinical Trial Implications In this episode of ChatGJP, Panome Bio President and Co-Founder Tom Cohen explores the growing field of exposomics and its role in understanding how environmental exposures influence human health and disease. Tom also discusses PFAS (per- and polyfluoroalkyl substances), a class of persistent “forever chemicals” found in virtually […]
In exposomics, there are two fundamentally different ways to explore the chemical world influencing human health and choosing the right one can make or break your study. Think of it like this: Are you searching for something specific or are you trying to discover what you don’t yet know exists? That’s the difference between targeted […]
Pinpointing the Pervasive: Exposomics Analysis of Alzheimer’s Disease This poster presents a comprehensive exposomics analysis of Alzheimer’s disease, leveraging both targeted and discovery workflows to characterize environmental exposures and their biological impact. By capturing a broad spectrum of exogenous compounds—including pollutants, dietary components, pharmaceuticals, and microbiome-derived metabolites—this work highlights the critical role of the exposome […]
Exposomics Measuring Chemical Drivers of Human Disease Panome Bio’s Exposomics platform enables comprehensive measurement of chemical exposures that drive human disease. Using integrated discovery (32,000+ compounds) and targeted profiling (235 priority chemicals), we detect and quantify exogenous exposures at trace levels. Demonstrated in Alzheimer’s disease, our workflow reveals disease-associated environmental signatures with high sensitivity and […]
Discover how targeted metabolomics enables more accurate evaluation of PRMT5 therapies, supports biomarker discovery, and drives translational breakthroughs in oncology in this webinar.
For 20 years, genomics has promised precision medicine. And it delivered. For rare diseases and select cancers. But for most chronic conditions? Genetics explains only a fraction of risk. Type 2 diabetes. Alzheimer’s disease. Autoimmune disorders. Metabolic syndrome. The missing piece isn’t hidden in undiscovered genes. It’s in the chemical world around us. Welcome to the […]